Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche's first-half sales hit by poor exchange rate and further Tamiflu decline

This article was originally published in Scrip

Executive Summary

Roche's pharmaceutical sales for the first half of this year were down by 6% to CHF17.3 billion ($17 billion) when compared with the same period last year, but increased by 3% in local currencies. Roche Pharmaceuticals' sales were down by 4% at CHF11 billion andChugai, of which Roche owns 59.9%, had sales of CHF1.5 billion, down by 13%.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts